11月26日，凯盛新材盘中下跌2.18%，截至09:48，报25.13元/股，成交1.86亿元，换手率1.87%，总市值 105.71亿元。 资金流向方面，主力资金净流出3209.81万元，特大单买入843.14万元，占比4.53%，卖出1618.25万元， 占比8.69%；大单买入2896.72万元，占比15.56%，卖出5331.43万元，占比28.64%。 凯盛新材今年以来股价涨70.72%，近5个交易日跌3.05%，近20日涨6.08%，近60日涨11.29%。 凯盛新材所属申万行业为：基础化工-化学原料-其他化学原料。所属概念板块包括：代糖概念、锂电 池、新材料、融资融券、中盘等。 截至11月10日，凯盛新材股东户数3.95万，较上期增加10.98%；人均流通股9910股，较上期减少 9.90%。2025年1月-9月，凯盛新材实现营业收入7.74亿元，同比增长11.22%；归母净利润1.16亿元，同 比增长121.56%。 分红方面，凯盛新材A股上市后累计派现2.94亿元。近三年，累计派现1.89亿元。 机构持仓方面，截止2025年9月30日，凯盛新材十大流通股东中，香港中央结算有限公司位居第七大流 ...

资料显示，山东凯盛新材料股份有限公司位于山东省淄博市淄川区双杨镇(张博公路东侧)，成立日期 2005年12月20日，上市日期2021年9月27日，公司主营业务涉及精细化工产品及新型高分子材料的研 发、生产和销售。主营业务收入构成为：羧基氯化物59.25%，无机化学品26.23%，羟基氯化物 13.93%，其他(补充)0.58%。 凯盛新材所属申万行业为：基础化工-化学原料-其他化学原料。所属概念板块包括：代糖概念、锂电 池、小盘、新材料、融资融券等。 截至11月10日，凯盛新材股东户数3.95万，较上期增加10.98%；人均流通股9910股，较上期减少 9.90%。2025年1月-9月，凯盛新材实现营业收入7.74亿元，同比增长11.22%；归母净利润1.16亿元，同 比增长121.56%。 11月25日，凯盛新材盘中上涨2.07%，截至10:59，报24.21元/股，成交2.70亿元，换手率2.88%，总市值 101.84亿元。 资金流向方面，主力资金净流出705.29万元，特大单买入721.85万元，占比2.68%，卖出1953.37万元， 占比7.25%；大单买入6756.76万元，占比25.07%，卖 ...

来源：新浪证券-红岸工作室 11月24日，百龙创园涨3.74%，成交额9154.56万元，换手率1.09%，总市值84.97亿元。 异动分析 资金分析 今日主力净流入-359.05万，占比0.04%，行业排名124/181，连续3日被主力资金减仓；所属行业主力净 流入-10.54亿，连续3日被主力资金减仓。 区间今日近3日近5日近10日近20日主力净流入-359.05万-1093.77万-2039.85万-2870.77万-870.32万 主力没有控盘，筹码分布非常分散，主力成交额3108.10万，占总成交额的9.71%。 2、2024年半年报，公司持有山东禹城农村商业银行股份有限公司 5.14%股份。 3、根据2024年年报，公司海外营收占比为60.62%，受益于人民币贬值。 4、专精特新"小巨人"企业是全国中小企业评定工作中最高等级、最具权威的荣誉称号，是指专注于细 分市场、创新能力强、市场占有率高、掌握关键核心技术、质量效益优的排头兵企业，对于提升中小企 业自身的竞争力，以及提升产业链、供应链稳定性和竞争力具有重大意义。公司已入选工信部专精特新 小巨人企业名单。 (免责声明：分析内容来源于互联网，不构成 ...

资金流入比率方面，华资实业、三达膜、百龙创园等流入比率居前，主力资金净流入率分别为 31.12%、10.70%、4.32%。（数据宝） 代糖概念资金流入榜 | 代码 简称 | 今日涨跌幅 | 今日换手率 | 主力资金流量（万 | 主力资金净流入比率 | | --- | --- | --- | --- | --- | | | （%） | （%） | 元） | （%） | | 688101 三达膜 | | 6.72 | 4539.60 | 10.70 | | 华资实 600191 业 | 10.00 | 2.13 | 3289.11 | 31.12 | | 百龙创 605016 园 | -1.82 | 0.56 | 207.64 | 4.32 | | 金河生 002688 物 | -0.65 | 1.21 | 173.05 | 3.10 | | 丰原药 000153 业 | -0.44 | 2.07 | 150.21 | 2.33 | | 华康股 605077 份 | -1.80 | 0.65 | 81.21 | 2.43 | | 301206 三元生 物 | -0.67 | 0.98 | 33.86 | 0.9 ...

11月19日，醋化股份盘中下跌2.15%，截至10:46，报12.28元/股，成交1447.41万元，换手率0.57%，总 市值25.11亿元。 醋化股份今年以来股价涨32.47%，近5个交易日跌2.54%，近20日涨0.00%，近60日跌5.10%。 资料显示，南通醋酸化工股份有限公司位于江苏省南通经济技术开发区江山路968号，成立日期，上市 日期2015年5月18日，公司主营业务涉及从事以醋酸衍生物、吡啶衍生物为主体的高端专用精细化学品 的研发、生产和销售。主营业务收入构成为：食品饲料添加剂28.53%，医药农药中间体20.29%，农化 类17.09%，其他商品12.51%，颜(染)料中间体11.97%，其他有机化合物7.19%，其他(补充)2.41%。 醋化股份所属申万行业为：基础化工-化学制品-食品及饲料添加剂。所属概念板块包括：微盘股、小 盘、代糖概念等。 截至9月30日，醋化股份股东户数1.16万，较上期减少13.79%；人均流通股17697股，较上期增加 15.99%。2025年1月-9月，醋化股份实现营业收入19.91亿元，同比减少9.44%；归母净利润-2423.02万 元，同比增长74.1 ...

Core Viewpoint - The company, Shandong Bailong Chuangyuan Biotechnology Co., Ltd., is experiencing a decline in stock price while benefiting from its unique product offerings and strategic investments, particularly in the context of the depreciating RMB and its recognition as a "specialized, refined, distinctive, and innovative" enterprise. Group 1: Company Overview - The company specializes in the research, production, and sales of prebiotics, dietary fibers, and healthy sweeteners, with a revenue composition of 54.15% from dietary fibers, 28.00% from prebiotics, 13.57% from healthy sweeteners, and 3.91% from other products [8] - As of October 31, the company had 13,400 shareholders, an increase of 3.75% from the previous period, with an average of 31,274 circulating shares per shareholder, a decrease of 3.62% [8] - The company reported a revenue of 969 million yuan for the period from January to September 2025, representing an 18.10% year-on-year growth, and a net profit of 265 million yuan, up 44.93% year-on-year [8] Group 2: Market Position and Financials - The company holds a 5.14% stake in Shandong Yucheng Rural Commercial Bank, which may provide additional financial stability and growth opportunities [3] - The overseas revenue accounted for 60.62% of total revenue, benefiting from the depreciation of the RMB [4] - The company has distributed a total of 183 million yuan in dividends since its A-share listing, with 172 million yuan distributed over the past three years [9] Group 3: Investment Highlights - The company produces allulose, a rare monosaccharide that serves as a low-calorie sugar substitute, making it ideal for individuals with obesity and diabetes [2] - The company has been recognized as a "specialized, refined, distinctive, and innovative" enterprise, which enhances its competitiveness and stability within the industry [4] - The stock has seen a recent decline of 2.07%, with a trading volume of 96.14 million yuan and a market capitalization of 8.753 billion yuan [1]

Group 1 - The core point of the news is that Baolingbao's stock price has experienced fluctuations, with a current price of 10.60 CNY per share, reflecting a year-to-date increase of 44.81% [1] - As of November 17, Baolingbao's market capitalization stands at 4.034 billion CNY, with a trading volume of 76.62 million CNY and a turnover rate of 1.93% [1] - The company has seen a net outflow of 5.7993 million CNY in principal funds, with significant buying and selling activity from large orders [1] Group 2 - Baolingbao Biotech Co., Ltd. is located in Dezhou, Shandong Province, and was established on October 16, 1997, with its listing date on August 28, 2009 [2] - The company's main business involves the research, production, and sales of functional sugars, with revenue composition including starch sugars (29.89%), sugar substitutes (26.55%), feed and by-products (22.40%), probiotics (13.48%), dietary fibers (7.39%), and others (0.29%) [2] - For the period from January to September 2025, Baolingbao achieved a revenue of 2.126 billion CNY, representing a year-on-year growth of 15.98%, and a net profit attributable to shareholders of 134 million CNY, up 32.58% [2]

Core Viewpoint - The stock of Baolingbao has shown significant growth this year, with a notable increase in both stock price and trading volume, indicating strong market interest and performance [1][2]. Group 1: Stock Performance - As of November 12, Baolingbao's stock price increased by 2.16% to 11.36 CNY per share, with a trading volume of 1.22 billion CNY and a turnover rate of 2.94%, resulting in a total market capitalization of 4.323 billion CNY [1]. - Year-to-date, Baolingbao's stock price has risen by 55.19%, with a 15.56% increase over the last five trading days, 13.94% over the last 20 days, and 5.87% over the last 60 days [1]. Group 2: Capital Flow - The net outflow of main funds was 6.5193 million CNY, with large orders showing a buy of 19.1894 million CNY (15.72% of total) and a sell of 23.0777 million CNY (18.91% of total) [1]. - Baolingbao has appeared on the "Dragon and Tiger List" five times this year, with the most recent instance on May 22, where the net buy was -50.8373 million CNY [1]. Group 3: Company Overview - Baolingbao Biotechnology Co., Ltd. was established on October 16, 1997, and listed on August 28, 2009, focusing on the research, production, and sales of functional sugars [2]. - The company's main business revenue composition includes starch sugars and others (29.89%), sugar-reducing sweeteners (26.55%), feed and by-products (22.40%), probiotics (13.48%), dietary fiber (7.39%), and others (0.29%) [2]. - As of October 31, the number of shareholders was 33,600, a decrease of 0.25%, with an average of 10,999 circulating shares per person, an increase of 0.25% [2]. Group 4: Financial Performance - For the period from January to September 2025, Baolingbao achieved a revenue of 2.126 billion CNY, representing a year-on-year growth of 15.98%, and a net profit attributable to shareholders of 134 million CNY, up by 32.58% [2]. - Since its A-share listing, Baolingbao has distributed a total of 309 million CNY in dividends, with 95.0722 million CNY distributed over the past three years [2].

Core Viewpoint - Jinhe Industrial's stock price has shown fluctuations, with a recent increase of 2.04%, but a year-to-date decline of 6.81%, indicating potential volatility in the market [1][2]. Company Overview - Jinhe Industrial, established on December 25, 2006, and listed on July 7, 2011, is located in Chuzhou, Anhui Province. The company specializes in the research, production, and sales of food additives, functional chemical products, and various high-end intermediates, serving sectors such as food and beverage, daily consumer goods, healthcare, agriculture, and advanced manufacturing [1][2]. - The revenue composition of Jinhe Industrial includes: food additives (48.10%), bulk chemicals (37.84%), functional chemical products and intermediates (5.34%), others (4.08%), electricity (3.27%), pharmaceutical intermediates (1.30%), and trade (0.08%) [1]. Financial Performance - For the period from January to September 2025, Jinhe Industrial reported a revenue of 3.543 billion yuan, a year-on-year decrease of 12.35%, and a net profit attributable to shareholders of 391 million yuan, down 4.44% year-on-year [2]. - Since its A-share listing, Jinhe Industrial has distributed a total of 3.017 billion yuan in dividends, with 1.005 billion yuan distributed over the past three years [3]. Shareholder Information - As of September 30, 2025, the number of shareholders for Jinhe Industrial reached 39,000, an increase of 14.63% from the previous period, while the average circulating shares per person decreased by 12.76% to 14,516 shares [2]. - The top ten circulating shareholders include Hong Kong Central Clearing Limited as the second-largest shareholder with 12.904 million shares, a decrease of 749,600 shares from the previous period. Other notable shareholders include Southern CSI 1000 ETF and Huaxia CSI 1000 ETF, with changes in their holdings [3].

来源：新浪证券-红岸工作室 11月7日，百龙创园涨1.00%，成交额9553.56万元，换手率1.08%，总市值88.83亿元。 (免责声明：分析内容来源于互联网，不构成投资建议，请投资者根据不同行情独立判断) 资金分析 今日主力净流入461.51万，占比0.05%，行业排名53/181，连续2日被主力资金增仓；所属行业主力净流 入33.32亿，连续3日被主力资金增仓。 异动分析 区间今日近3日近5日近10日近20日主力净流入461.51万363.63万-244.30万1236.16万565.01万 代糖概念+参股银行+人民币贬值受益+专精特新 1、公司生产的健康甜味剂产品主要为阿洛酮糖，阿洛酮糖是在自然界中天然存在但含量极少的一种稀 有单糖，其甜味及口感与蔗糖相当类似或接近，但其热量却远低于蔗糖，对于肥胖以及糖尿病患者是一 种理想的蔗糖代替物。 2、2024年半年报，公司持有山东禹城农村商业银行股份有限公司 5.14%股份。 3、根据2024年年报，公司海外营收占比为60.62%，受益于人民币贬值。 4、专精特新"小巨人"企业是全国中小企业评定工作中最高等级、最具权威的荣誉称号，是指专注于细 分市场、创新能 ...